Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics (Nature Reviews Gastroenterology & Hepatology, (2021), 18, 9, (649-667), 10.1038/s41575-021-00440-6);The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics

Nature Reviews Gastroenterology and Hepatology

Volumn 18, Issue 9, 2021, Pages 649-667

  Salminen, Seppo ^a   Collado, Maria Carmen ^b   Endo, Akihito ^c   Hill, Colin ^d,e   Lebeer, Sarah ^f   Quigley, Eamonn M M ^g   Sanders, Mary Ellen ^h   Shamir, Raanan ^i,j   Swann, Jonathan R ^k,l   Szajewska, Hania ^m   Vinderola, Gabriel ⁿ  

^a UNIVERSITY OF TURKU   (Finland)

^b INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^c TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY COLLEGE CORK   (Ireland)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h International Scientific Association for Probiotics and Prebiotics   (United States)

ⁱ SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^j TEL AVIV UNIVERSITY   (Israel)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁿ UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BACTERIOCIN; BIFIDOBACTERIUM BREVE EXTRACT; CHEMOKINE RECEPTOR CX3CR1; CLARITHROMYCIN; EXOPOLYSACCHARIDE; HEAT KILLED PROBIOTIC AGENT; HYDROLASE; LACIDOPHILIN; LACTOBACILLUS CASEI EXTRACT; NON VIABLE PROBIOTIC AGENT; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; POSTBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; RABEPRAZOLE; SHORT CHAIN FATTY ACID; STREPTOCOCCUS THERMOPHILUS EXTRACT; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TYNDALLIZED PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; ADULT; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ATOMIC FORCE SPECTROSCOPY; ATOPIC DERMATITIS; BACILLUS COAGULANS; BIFIDOBACTERIUM; BIOMASS PRODUCTION; COLONY FORMING UNIT; CONSENSUS DEVELOPMENT; DROPLET DIGITAL POLYMERASE CHAIN REACTION; DRUG ANALYSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FERMENTED PRODUCT; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; FOOD INDUSTRY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; FREEZE DRYING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; IONIZING RADIATION; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS RHAMNOSUS; LACTOSE INTOLERANCE; MICROBIAL IDENTIFICATION; MICROBIAL METABOLISM; MILK ALLERGY; MYCOBACTERIUM PHLEI; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; PREMATURITY; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SCANNING ELECTRON MICROSCOPY; SCIENTIFIC LITERATURE; SHELF LIFE; SIGNAL TRANSDUCTION; SPRAY DRYING; TEMPERATURE STRESS; TH1 CELL; TRANSGENIC ORGANISM; ULTRASOUND ASSISTED EXTRACTION; WHEY; HEALTH CARE ORGANIZATION;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; PREBIOTICS; PROBIOTICS; SOCIETIES, SCIENTIFIC;

EID: 85104382547     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/s41575-021-00481-x     Document Type: Erratum

References (191)

1. Selma-Royo, M. et al. Shaping microbiota during the first 1000 days of life. Adv. Exp. Med. Biol. 1125, 3–24 (2019). DOI: 10.1007/5584_2018_312
2. Mills, S., Stanton, C., Lane, J. A., Smith, G. J. & Ross, R. P. Precision nutrition and the microbiome, Part I: current state of the science. Nutrients 11, 923 (2019). DOI: 10.3390/nu11040923
3. Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014). DOI: 10.1038/nrgastro.2014.66
4. Gibson, G. R. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502 (2017). DOI: 10.1038/nrgastro.2017.75
5. Swanson, K. S. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 17, 687–701 (2020). DOI: 10.1038/s41575-020-0344-2
6. Fiore, W., Arioli, S. & Guglielmetti, S. The neglected microbial components of commercial probiotic formulations. Microorganisms 8, 1177 (2020). DOI: 10.3390/microorganisms8081177
7. Holmes, E. et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl Med. 4, 137rv136 (2012). DOI: 10.1126/scitranslmed.3004244
8. Marco, M. L. et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. Nat. Rev. Gastroenterol. Hepatol. 18, 196–208 (2021). DOI: 10.1038/s41575-020-00390-5
9. Marco, M. L. et al. Health benefits of fermented foods: microbiota and beyond. Curr. Opin. Biotechnol. 44, 94–102 (2017). DOI: 10.1016/j.copbio.2016.11.010
10. Esposito, S. et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr. Opin. Allergy Clin. Immunol. 18, 198–209 (2018). DOI: 10.1097/ACI.0000000000000433
11. Deshpande, G., Athalye-Jape, G. & Patole, S. Para-probiotics for preterm neonates–the next frontier. Nutrients 10, 871 (2018). DOI: 10.3390/nu10070871
12. Kanauchi, O., Andoh, A., AbuBakar, S. & Yamamoto, N. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr. Pharm. Des. 24, 710–717 (2018). DOI: 10.2174/1381612824666180116163411
13. Murata, M. et al. Effects of paraprobiotic Lactobacillus paracasei MCC1849 supplementation on symptoms of the common cold and mood states in healthy adults. Benef. Microbes 9, 855–864 (2018). DOI: 10.3920/BM2017.0197
14. Sugawara, T. et al. Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function. Microb. Ecol. Health Dis. 27, 30259 (2016).
15. Nishida, K. et al. Para-psychobiotic Lactobacillus gasseri CP2305 ameliorates stress-related symptoms and sleep quality. J. Appl. Microbiol. 123, 1561–1570 (2017). DOI: 10.1111/jam.13594
16. Taverniti, V. & Guglielmetti, S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 6, 261–274 (2011). DOI: 10.1007/s12263-011-0218-x
17. Sharma, M., Chandel, D. & Shukla, G. Antigenotoxicity and cytotoxic potentials of metabiotics extracted from isolated probiotic, Lactobacillus rhamnosus MD 14 on Caco-2 and HT-29 human colon cancer cells. Nutr. Cancer 72, 110–119 (2020). DOI: 10.1080/01635581.2019.1615514
18. Shenderov, B. A. Metabiotics: novel idea or natural development of probiotic conception. Microb. Ecol. Health Dis. 24, 20399 (2013).
19. Pique, N., Berlanga, M. & Minana-Galbis, D. Health benefits of heat-killed (tyndallized) probiotics: an overview. Int. J. Mol. Sci. 20, 2534 (2019). DOI: 10.3390/ijms20102534
20. Lopetuso, L. et al. Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea. Eur. Rev. Med. Pharmacol. Sci. 21, 873–883 (2017).
21. Jurkiewicz, D. & Zielnik-Jurkiewicz, B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol. Pol. 72, 1–8 (2018). DOI: 10.5604/01.3001.0012.7216
22. Zheng, J. et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int. J. Syst. Evol. Microbiol. 70, 2782–2858 (2020). DOI: 10.1099/ijsem.0.004107
23. Cicenia, A. et al. Postbiotic activities of lactobacilli-derived factors. J. Clin. Gastroenterol. 48 (Suppl. 1), S18–S22 (2014). DOI: 10.1097/MCG.0000000000000231
24. Patel, R. M. & Denning, P. W. Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence? Clin. Perinatol. 40, 11–25 (2013). DOI: 10.1016/j.clp.2012.12.002
25. Andresen, V., Gschossmann, J. & Layer, P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol. Hepatol. 5, 658–666 (2020). DOI: 10.1016/S2468-1253(20)30056-X
26. Aguilar-Toala, J. E. et al. In silico prediction and in vitro assessment of multifunctional properties of postbiotics obtained from two probiotic bacteria. Probiotics Antimicrob. Proteins 12, 608–622 (2019). DOI: 10.1007/s12602-019-09568-z
27. Martin, R. et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front. Microbiol. 8, 1226 (2017). DOI: 10.3389/fmicb.2017.01226
28. Brodmann, T. et al. Safety of novel microbes for human consumption: practical examples of assessment in the European Union. Front. Microbiol. 8, 1725 (2017). DOI: 10.3389/fmicb.2017.01725
29. Breyner, N. M. et al. Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-induced colitis model in mice through inhibition of NF-κB pathway. Front. Microbiol. 8, 114 (2017). DOI: 10.3389/fmicb.2017.00114
30. Cani, P. D. & de Vos, W. M. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front. Microbiol. 8, 1765 (2017). DOI: 10.3389/fmicb.2017.01765
31. European Medicines Agency. Assessment report. Referral under Article 31 of Directive 2001/83/EC. Bacterial lysates-containing medicinal products for respiratory conditions. EMA https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-chmp-assessment-report_en.pdf (2019).
32. Cardinale, F. et al. Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. Expert Rev. Respir. Med. 14, 1019–1026 (2020). DOI: 10.1080/17476348.2020.1793673
33. Huber, M., Mossmann, H. & Bessler, W. G. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur. J. Med. Res. 10, 209–217 (2005).
34. Braido, F., Tarantini, F., Ghiglione, V., Melioli, G. & Canonica, G. W. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int. J. Chron. Obstruct Pulmon Dis. 2, 335–345 (2007).
35. Braido, F. et al. The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial. Immunol. Lett. 162, 185–193 (2014). DOI: 10.1016/j.imlet.2014.10.026
36. Morandi, B. et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol. Lett. 138, 86–91 (2011). DOI: 10.1016/j.imlet.2011.03.006
37. Lanzilli, G. et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, B and NK cells. Immunol. Lett. 149, 62–67 (2013). DOI: 10.1016/j.imlet.2012.11.009
38. Rossi, G. A. et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol. Lett. 86, 85–91 (2003). DOI: 10.1016/S0165-2478(02)00290-0
39. Braido, F. et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Pulm. Pharmacol. Ther. 33, 75–80 (2015). DOI: 10.1016/j.pupt.2015.03.006
40. Zarezadeh, M. et al. Spirulina supplementation and anthropometric indices: a systematic review and meta-analysis of controlled clinical trials. Phytother Res. 35, 577–586 (2021). DOI: 10.1002/ptr.6834
41. Mitsuoka, T. Intestinal Flora and Probiotics (Gakkai Shuppan Center, 1998).
42. Kamioka, H. et al. Quality of systematic reviews of the Foods With Function Claims registered at the Consumer Affairs Agency Web site in Japan: a prospective systematic review. Nutr. Res. 40, 21–31 (2017). DOI: 10.1016/j.nutres.2017.02.008
43. Nakamura, F. et al. Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial. Microb. Ecol. Health Dis. 27, 30312 (2016).
44. Morita, Y., Jounai, K., Miyake, M., Inaba, M. & Kanauchi, O. Effect of heat-killed Lactobacillus paracasei KW3110 ingestion on ocular disorders caused by visual display terminal (VDT) loads: a randomized, double-blind, placebo-controlled parallel-group study. Nutrients 10, 1058 (2018). DOI: 10.3390/nu10081058
45. Maeda-Yamamoto, M. & Ohtani, T. Development of functional agricultural products utilizing the new health claim labeling system in Japan. Biosci. Biotechnol. Biochem. 82, 554–563 (2018). DOI: 10.1080/09168451.2017.1422175
46. Yin, J., Xu, B., Zeng, X. & Shen, K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. Int. Immunopharmacol. 54, 198–209 (2018). DOI: 10.1016/j.intimp.2017.10.032
47. European Food Safety Authority. Scientific Opinion on the safety of heat-treated milk products fermented with Bacteroides xylanisolvens DSM 23964 as a novel food. EFSA J. 13, 3956 (2015). DOI: 10.2903/j.efsa.2015.3956
48. Council of Europe. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. European Commission https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf (2004).
49. Council of Europe. European Pharmacopoeia 7.0: 5.1.4. Microbiological quality of non-streile pharmaceutical preparations and substances for pharmaceutical use. Medicinal Genomics https://www.medicinalgenomics.com/wp-content/uploads/2013/04/CFU_Tolerance_European.pdf (2011).
50. Council of Europe. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745&from=EN (2017).
51. Binetti, A., Burns, P., Tomei, D., Reinheimer, J. & Vinderola, G. in Lactic Acid Bacteria, Microbiological and Functional Aspects Ch. 39 (eds Vinderola, G., Salminen, S., Ouwehand, A. & von Wright, A.) (CRC, 2019).
52. Food and Drug Administration. What does FDA regulate? FDA https://www.fda.gov/about-fda/fda-basics/what-does-fda-regulate (2021).
53. Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019). DOI: 10.1038/s41591-019-0626-9
54. Periti, P. & Mazzei, T. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. J. Chemother. 10, 427–448 (1998). DOI: 10.1179/joc.1998.10.6.427
55. Yıkmıs¸, S. New approaches in non-thermal processes in the food industry. Int. J. Nutr. Food Sci. 5, 344–351 (2016). DOI: 10.11648/j.ijnfs.20160505.15
56. Barba, F. J., Kouba, M., do Prado-Silvac, L., Orlien, V. & Sant’Anac, A. D. S. Mild processing applied to the inactivation of the main foodborne bacterial pathogens: a review. Trends Food Sci. Technol. 66, 20–35 (2017). DOI: 10.1016/j.tifs.2017.05.011
57. Charoux, C. M. G. et al. Effect of non-thermal plasma technology on microbial inactivation and total phenolic content of a model liquid food system and black pepper grains. LWT 118, 108716 (2020). DOI: 10.1016/j.lwt.2019.108716
58. Fu, N., Huang, S., Xiao, J. & Chen, X. D. Producing powders containing active dry probiotics with the aid of spray drying. Adv. Food Nutr. Res. 85, 211–262 (2018). DOI: 10.1016/bs.afnr.2018.02.003
59. Szajewska, H., Skorka, A. & Piescik-Lech, M. Fermented infant formulas without live bacteria: a systematic review. Eur. J. Pediatr. 174, 1413–1420 (2015). DOI: 10.1007/s00431-015-2629-y
60. Broeckx, G., Vandenheuvel, D., Claes, I. J., Lebeer, S. & Kiekens, F. Drying techniques of probiotic bacteria as an important step towards the development of novel pharmabiotics. Int. J. Pharm. 505, 303–318 (2016). DOI: 10.1016/j.ijpharm.2016.04.002
61. Roohinejad, S., Koubaa, M., Sant’Ana, A. S. & Greiner, R. in Innovative Technologies for Food Preservation (eds Orlien, V., Sant’Ana, A. S., Barba, F. J., & Koubaa, M.) 111–132 (2018).
62. Iaconelli, C. et al. Drying process strongly affects probiotics viability and functionalities. J. Biotechnol. 214, 17–26 (2015). DOI: 10.1016/j.jbiotec.2015.08.022
63. Tabanelli, G. et al. Effect of a non-lethal high pressure homogenization treatment on the in vivo response of probiotic lactobacilli. Food Microbiol. 32, 302–307 (2012). DOI: 10.1016/j.fm.2012.07.004
64. Lebeer, S. et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl. Env. Microbiol. 78, 185–193 (2012). DOI: 10.1128/AEM.06192-11
65. Verma, T., Chaves, B. D., Howell, T. Jr. & Subbiah, J. Thermal inactivation kinetics of Salmonella and Enterococcus faecium NRRL B-2354 on dried basil leaves. Food Microbiol. 96, 103710 (2021). DOI: 10.1016/j.fm.2020.103710
66. Ruiling, L., Donghong, L. & Jianwei, Z. Bacterial spore inactivation by non-thermal technologies: resistance and inactivation mechanisms. Curr. Opin. Food Sci. 42, 31–36 (2021). DOI: 10.1016/j.cofs.2020.12.014
67. Jambrak, A. R., Vukušic´, T., Donsi, F., Paniwnyk, L. & Djekic, I. Three pillars of novel nonthermal food technologies: food safety, quality, and environment. J. Food Quality 2018, 8619707 (2018).
68. Chiron, C., Tompkins, T. A. & Burguiere, P. Flow cytometry: a versatile technology for specific quantification and viability assessment of micro-organisms in multistrain probiotic products. J. Appl. Microbiol. 124, 572–584 (2018). DOI: 10.1111/jam.13666
69. Savijoki, K. et al. Growth mode and carbon source impact the surfaceome dynamics of Lactobacillus rhamnosus GG. Front. Microbiol. 10, 1272 (2019). DOI: 10.3389/fmicb.2019.01272
70. Kramer, M., Obermajer, N., Bogovic Matijasic, B., Rogelj, I. & Kmetec, V. Quantification of live and dead probiotic bacteria in lyophilised product by real-time PCR and by flow cytometry. Appl. Microbiol. Biotechnol. 84, 1137–1147 (2009). DOI: 10.1007/s00253-009-2068-7
71. Gobert, G. et al. Droplet digital PCR improves absolute quantification of viable lactic acid bacteria in faecal samples. J. Microbiol. Methods 148, 64–73 (2018). DOI: 10.1016/j.mimet.2018.03.004
72. Hansen, S. J. Z. et al. Droplet digital PCR is an improved alternative method for high-quality enumeration of viable probiotic strains. Front. Microbiol. 10, 3025 (2019). DOI: 10.3389/fmicb.2019.03025
73. Himmelreich, U., Sorrell, T. C. & Daniel, H. M. Nuclear magnetic resonance spectroscopy-based identification of yeast. Methods Mol. Biol. 1508, 289–304 (2017). DOI: 10.1007/978-1-4939-6515-1_17
74. Francius, G. et al. Stretching polysaccharides on live cells using single molecule force spectroscopy. Nat. Protoc. 4, 939–946 (2009). DOI: 10.1038/nprot.2009.65
75. Kiekens, S. et al. Impact of spray-drying on the pili of Lactobacillus rhamnosus GG. Microb. Biotechnol. 12, 849–855 (2019). DOI: 10.1111/1751-7915.13426
76. Sankarganesh, P. & Joseph, B. Fourier transform infrared spectroscopy as a tool for identification of crude microbial extracts with anti-malarial potential. Acta Parasitol. 61, 98–101 (2016). DOI: 10.1515/ap-2016-0012
77. Rault, A., Bouix, M. & Béala, C. Cryotolerance of Lactobacillus delbrueckii subsp. bulgaricus CFL1 is influenced by the physiological state during fermentation. Int. Dairy. J. 20, 792–799 (2010). DOI: 10.1016/j.idairyj.2010.05.002
78. Lebeer, S. et al. Identification of probiotic effector molecules: present state and future perspectives. Curr. Opin. Biotechnol. 49, 217–223 (2018). DOI: 10.1016/j.copbio.2017.10.007
79. Sun, Z. et al. Expanding the biotechnology potential of lactobacilli through comparative genomics of 213 strains and associated genera. Nat. Commun. 6, 8322 (2015). DOI: 10.1038/ncomms9322
80. Corr, S. C. et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl Acad. Sci. USA 104, 7617–7621 (2007). DOI: 10.1073/pnas.0700440104
81. Grandclement, C., Tannieres, M., Morera, S., Dessaux, Y. & Faure, D. Quorum quenching: role in nature and applied developments. FEMS Microbiol. Rev. 40, 86–116 (2016). DOI: 10.1093/femsre/fuv038
82. Laverde Gomez, J. A. et al. Formate cross-feeding and cooperative metabolic interactions revealed by transcriptomics in co-cultures of acetogenic and amylolytic human colonic bacteria. Env. Microbiol. 21, 259–271 (2019). DOI: 10.1111/1462-2920.14454
83. Tytgat, H. L. et al. Lactobacillus rhamnosus GG outcompetes Enterococcus faecium via mucus-binding pili: evidence for a novel and heterospecific probiotic mechanism. Appl. Env. Microbiol. 82, 5756–5762 (2016). DOI: 10.1128/AEM.01243-16
84. Petrova, M. I. et al. Lectin-like molecules of Lactobacillus rhamnosus GG inhibit pathogenic Escherichia coli and Salmonella biofilm formation. PLoS ONE 11, e0161337 (2016). DOI: 10.1371/journal.pone.0161337
85. Yan, F. et al. A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. J. Biol. Chem. 288, 30742–30751 (2013). DOI: 10.1074/jbc.M113.492397
86. Gao, J. et al. A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function. Front. Microbiol. 10, 477 (2019). DOI: 10.3389/fmicb.2019.00477
87. Schiavi, E. et al. The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses. Appl. Env. Microbiol. 82, 7185–7196 (2016). DOI: 10.1128/AEM.02238-16
88. Engevik, M. A. et al. Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways. mBio 10, e01087-19 (2019). DOI: 10.1128/mBio.01087-19
89. Feng, Y., Wang, Y., Wang, P., Huang, Y. & Wang, F. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy. Cell Physiol. Biochem. 49, 190–205 (2018). DOI: 10.1159/000492853
90. Ohata, A., Usami, M. & Miyoshi, M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 21, 838–847 (2005). DOI: 10.1016/j.nut.2004.12.004
91. Lebeer, S., Vanderleyden, J. & De Keersmaecker, S. C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 8, 171–184 (2010). DOI: 10.1038/nrmicro2297
92. Mohamadzadeh, M. et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4623–4630 (2011). DOI: 10.1073/pnas.1005066107
93. Macho Fernandez, E. et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 60, 1050–1059 (2011). DOI: 10.1136/gut.2010.232918
94. Sabharwal, H., Cichon, C., Olschlager, T. A., Sonnenborn, U. & Schmidt, M. A. Interleukin-8, CXCL1, and microRNA miR-146a responses to probiotic Escherichia coli Nissle 1917 and enteropathogenic E. coli in human intestinal epithelial T84 and monocytic THP-1 cells after apical or basolateral infection. Infect. Immun. 84, 2482–2492 (2016). DOI: 10.1128/IAI.00402-16
95. Zhong, Y., Huang, J., Tang, W., Chen, B. & Cai, W. Effects of probiotics, probiotic DNA and the CpG oligodeoxynucleotides on ovalbumin-sensitized brown-Norway rats via TLR9/NF-κB pathway. FEMS Immunol. Med. Microbiol. 66, 71–82 (2012). DOI: 10.1111/j.1574-695X.2012.00991.x
96. Basic, M. et al. Loss of CD14 leads to disturbed epithelial-B cell crosstalk and impairment of the intestinal barrier after E. coli Nissle monoassociation. Sci. Rep. 8, 719 (2018). DOI: 10.1038/s41598-017-19062-7
97. Jin, X., Zhang, M. & Yang, Y. F. Saccharomyces cerevisiae β-glucan-induced SBD-1 expression in ovine ruminal epithelial cells is mediated through the TLR-2-MyD88-NF-κB/MAPK pathway. Vet. Res. Commun. 43, 77–89 (2019). DOI: 10.1007/s11259-019-09747-x
98. Sturm, A. et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect. Immun. 73, 1452–1465 (2005). DOI: 10.1128/IAI.73.3.1452-1465.2005
99. Luan, H. et al. OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells. J. Interferon Cytokine Res. 34, 526–536 (2014). DOI: 10.1089/jir.2013.0077
100. Morita, N. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1(+) cells by bacterial metabolites. Nature 566, 110–114 (2019). DOI: 10.1038/s41586-019-0884-1
101. Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8αα(+) T cells. Science 357, 806–810 (2017). DOI: 10.1126/science.aah5825
102. Thomas, C. M. et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS ONE 7, e31951 (2012). DOI: 10.1371/journal.pone.0031951
103. Thangaraju, M. et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69, 2826–2832 (2009). DOI: 10.1158/0008-5472.CAN-08-4466
104. Long, S. L., Gahan, C. G. M. & Joyce, S. A. Interactions between gut bacteria and bile in health and disease. Mol. Asp. Med. 56, 54–65 (2017). DOI: 10.1016/j.mam.2017.06.002
105. Travers, M. A. et al. Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic Lactobacillus johnsonii La1 inhibit Giardia duodenalis in vitro growth. Front. Microbiol. 7, 1453 (2016). DOI: 10.3389/fmicb.2016.01453
106. Mullish, B. H. et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68, 1791–1800 (2019). DOI: 10.1136/gutjnl-2018-317842
107. De Vadder, F. et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab. 24, 151–157 (2016). DOI: 10.1016/j.cmet.2016.06.013
108. Wolever, T. M., Fernandes, J. & Rao, A. V. Serum acetate:propionate ratio is related to serum cholesterol in men but not women. J. Nutr. 126, 2790–2797 (1996).
109. Hamer, H. M. et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin. Nutr. 28, 88–93 (2009). DOI: 10.1016/j.clnu.2008.11.002
110. Caspani, G. & Swann, J. Small talk: microbial metabolites involved in the signaling from microbiota to brain. Curr. Opin. Pharmacol. 48, 99–106 (2019). DOI: 10.1016/j.coph.2019.08.001
111. O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G. & Cryan, J. F. Serotonin, tryptophan metabolism and the brain–gut–microbiome axis. Behav. Brain Res. 277, 32–48 (2015). DOI: 10.1016/j.bbr.2014.07.027
112. Iwasaki, M., Akiba, Y. & Kaunitz, J. D. Duodenal chemosensing of short-chain fatty acids: implications for GI diseases. Curr. Gastroenterol. Rep. 21, 35 (2019). DOI: 10.1007/s11894-019-0702-9
113. Engevik, M. A. et al. Human-derived Bifidobacterium dentium modulates the mammalian serotonergic system and gut–brain axis. Cell Mol. Gastroenterol. Hepatol. 11, 221–248 (2021). DOI: 10.1016/j.jcmgh.2020.08.002
114. Byrne, C. S., Chambers, E. S., Morrison, D. J. & Frost, G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int. J. Obes. 39, 1331–1338 (2015). DOI: 10.1038/ijo.2015.84
115. Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744–1754 (2015). DOI: 10.1136/gutjnl-2014-307913
116. Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014). DOI: 10.1038/ncomms4611
117. Mohedano, M. L. et al. Real-time detection of riboflavin production by Lactobacillus plantarum strains and tracking of their gastrointestinal survival and functionality in vitro and in vivo using mCherry labeling. Front. Microbiol. 10, 1748 (2019). DOI: 10.3389/fmicb.2019.01748
118. Kennedy, D. O. Vitamins and the brain: mechanisms, dose and efficacy–a review. Nutrients 8, 68 (2016). DOI: 10.3390/nu8020068
119. Parkins, D. A. & Lashmar, U. T. The formulation of biopharmaceutical products. Pharm. Sci. Technol. Today 3, 129–137 (2000). DOI: 10.1016/S1461-5347(00)00248-0
120. Warda, A. K. et al. Heat-killed lactobacilli alter both microbiota composition and behaviour. Behav. Brain Res. 362, 213–223 (2019). DOI: 10.1016/j.bbr.2018.12.047
121. Warda, A. K. et al. Oral administration of heat-treated lactobacilli modifies the murine microbiome and reduces Citrobacter induced colitis. Front. Microbiol. 11, 69 (2020). DOI: 10.3389/fmicb.2020.00069
122. Canducci, F. et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther. 14, 1625–1629 (2000). DOI: 10.1046/j.1365-2036.2000.00885.x
123. Tarrerias, A. L. et al. The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig. Dis. 29, 588–591 (2011). DOI: 10.1159/000332987
124. Xiao, S. D. et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv. Ther. 20, 253–260 (2003). DOI: 10.1007/BF02849854
125. Nishida, K., Sawada, D., Kuwano, Y., Tanaka, H. & Rokutan, K. Health benefits of Lactobacillus gasseri CP2305 tablets in young adults exposed to chronic stress: a randomized, double-blind, placebo-controlled study. Nutrients 11, 1859 (2019). DOI: 10.3390/nu11081859
126. Jones, C. et al. Modulation of gut barrier function in patients with obstructive jaundice using probiotic LP299v. Eur. J. Gastroenterol. Hepatol. 25, 1424–1430 (2013). DOI: 10.1097/MEG.0b013e328363e26e
127. Hoffman, J. R. et al. The effect of 2 weeks of inactivated probiotic Bacillus coagulans on endocrine, inflammatory, and performance responses during self-defense training in soldiers. J. Strength. Cond. Res. 33, 2330–2337 (2019). DOI: 10.1519/JSC.0000000000003265
128. Montane, E. et al. Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: safety and immunogenicity. PLoS ONE 12, e0171294 (2017). DOI: 10.1371/journal.pone.0171294
129. Zhang, J., Guo, S., Li, C. & Jiang, X. Therapeutic effects of inhaled inactivated Mycobacterium phlei in adult patients with moderate persistent asthma. Immunotherapy 4, 383–387 (2012). DOI: 10.2217/imt.12.25
130. Tandon, M. K. et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 137, 805–811 (2010). DOI: 10.1378/chest.09-1382
131. Frank, M. G. et al. Immunization with Mycobacterium vaccae induces an anti-inflammatory milieu in the CNS: attenuation of stress-induced microglial priming, alarmins and anxiety-like behavior. Brain Behav. Immun. 73, 352–363 (2018). DOI: 10.1016/j.bbi.2018.05.020
132. Mohammedsaeed, W., Cruickshank, S., McBain, A. J. & O’Neill, C. A. Lactobacillus rhamnosus GG lysate increases re-epithelialization of keratinocyte scratch assays by promoting migration. Sci. Rep. 5, 16147 (2015). DOI: 10.1038/srep16147
133. Rinaldi, F., Trink, A. & Pinto, D. Efficacy of postbiotics in a PRP-like cosmetic product for the treatment of alopecia area Celsi: a randomized double-blinded parallel-group study. Dermatol. Ther. 10, 483–493 (2020). DOI: 10.1007/s13555-020-00369-9
134. Fernandez, L., Delgado, S., Herrero, H., Maldonado, A. & Rodriguez, J. M. The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J. Hum. Lact. 24, 311–316 (2008). DOI: 10.1177/0890334408317435
135. Kang, B. S. et al. Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol. 47, 101–109 (2009). DOI: 10.1007/s12275-008-0179-y
136. Puccetti, M., Giovagnoli, S., Zelante, T., Romani, L. & Ricci, M. Development of novel indole-3-aldehyde-loaded gastro-resistant spray-dried microparticles for postbiotic small intestine local delivery. J. Pharm. Sci. 107, 2341–2353 (2018). DOI: 10.1016/j.xphs.2018.04.023
137. Scheppach, W. et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103, 51–56 (1992). DOI: 10.1016/0016-5085(92)91094-K
138. Steinhart, A. H., Brzezinski, A. & Baker, J. P. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am. J. Gastroenterol. 89, 179–183 (1994).
139. Vernia, P. et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment. Pharmacol. Ther. 9, 309–313 (1995). DOI: 10.1111/j.1365-2036.1995.tb00386.x
140. Patz, J., Jacobsohn, W. Z., Gottschalk-Sabag, S., Zeides, S. & Braverman, D. Z. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am. J. Gastroenterol. 91, 731–734 (1996).
141. Steinhart, A. H., Hiruki, T., Brzezinski, A. & Baker, J. P. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment. Pharmacol. Ther. 10, 729–736 (1996). DOI: 10.1046/j.1365-2036.1996.d01-509.x
142. Scheppach, W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German–Austrian SCFA Study Group. Dig. Dis. Sci. 41, 2254–2259 (1996). DOI: 10.1007/BF02071409
143. Talley, N. A., Chen, F., King, D., Jones, M. & Talley, N. J. Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. Dis. Colon. Rectum 40, 1046–1050 (1997). DOI: 10.1007/BF02050927
144. Pinto, A. et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis. Colon. Rectum 42, 788–795 (1999). discussion 795-786. DOI: 10.1007/BF02236937
145. Vernia, P. et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 356, 1232–1235 (2000). DOI: 10.1016/S0140-6736(00)02787-2
146. Maggio, A. et al. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study. Int. J. Radiat. Oncol. Biol. Phys. 89, 518–524 (2014). DOI: 10.1016/j.ijrobp.2014.03.018
147. Vanhoutvin, S. A. et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol. Motil. 21, 952–e76 (2009). DOI: 10.1111/j.1365-2982.2009.01324.x
148. Guillemot, F. et al. Treatment of diversion colitis by short-chain fatty acids. Prospective double-blind study. Dis. Colon. Rectum 34, 861–864 (1991). DOI: 10.1007/BF02049697
149. Luceri, C. et al. Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: a randomized trial. Dig. Liver Dis. 48, 27–33 (2016). DOI: 10.1016/j.dld.2015.09.005
150. Tominaga, K. et al. Diversion colitis and pouchitis: a mini-review. World J. Gastroenterol. 24, 1734–1747 (2018). DOI: 10.3748/wjg.v24.i16.1734
151. Caluwaerts, S. et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral. Oncol. 46, 564–570 (2010). DOI: 10.1016/j.oraloncology.2010.04.008
152. Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl Med. 11, eaau7975 (2019). DOI: 10.1126/scitranslmed.aau7975
153. Kurtz, C. et al. Translational development of microbiome-based therapeutics: kinetics of E. coli Nissle and engineered strains in humans and nonhuman primates. Clin. Transl Sci. 11, 200–207 (2018). DOI: 10.1111/cts.12528
154. Robert, S. & Steidler, L. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the type 1 diabetes case. Microb. Cell Fact. 13 (Suppl. 1), 11 (2014). DOI: 10.1186/1475-2859-13-S1-S11
155. Takiishi, T. et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122, 1717–1725 (2012). DOI: 10.1172/JCI60530
156. Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010). DOI: 10.1038/mi.2009.116
157. Frossard, C. P., Steidler, L. & Eigenmann, P. A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin. Immunol. 119, 952–959 (2007). DOI: 10.1016/j.jaci.2006.12.615
158. Reardon, S. Genetically modified bacteria enlisted in fight against disease. Nature 558, 497–498 (2018). DOI: 10.1038/d41586-018-05476-4
159. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP). et al. Safety and nutritional value of a dried killed bacterial biomass from Escherichia coli (FERM BP-10941) (PL73 (LM)) as a feed material for pigs, ruminants and salmonids. EFSA J. 15, e04935 (2017).
160. Agostoni, C. et al. Fermented infant formulae without live bacteria. J. Pediatr. Gastroenterol. Nutr. 44, 392–397 (2007). DOI: 10.1097/01.mpg.0000258887.93866.69
161. Campeotto, F. et al. A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. Br. J. Nutr. 105, 1843–1851 (2011). DOI: 10.1017/S0007114510005702
162. Szajewska, H., Ruszczynski, M. & Kolacek, S. Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatr. 103, 249–255 (2014). DOI: 10.1111/apa.12487
163. Kaila, M., Isolauri, E., Saxelin, M., Arvilommi, H. & Vesikari, T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch. Dis. Child. 72, 51–53 (1995). DOI: 10.1136/adc.72.1.51
164. Mantziari, A., Salminen, S., Szajewska, H. & Malagon-Rojas, J. N. Postbiotics against pathogens commonly involved in pediatric infectious diseases. Microorganisms 8, 1510 (2020). DOI: 10.3390/microorganisms8101510
165. Nocerino, R. et al. Cow’s milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: a randomized controlled trial. Clin. Nutr. 36, 118–125 (2017). DOI: 10.1016/j.clnu.2015.12.004
166. Thibault, H., Aubert-Jacquin, C. & Goulet, O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J. Pediatr. Gastroenterol. Nutr. 39, 147–152 (2004). DOI: 10.1097/00005176-200408000-00004
167. Sharieff, W., Bhutta, Z., Schauer, C., Tomlinson, G. & Zlotkin, S. Micronutrients (including zinc) reduce diarrhoea in children: the Pakistan Sprinkles Diarrhoea Study. Arch. Dis. Child. 91, 573–579 (2006). DOI: 10.1136/adc.2005.086199
168. Corsello, G. et al. Preventive effect of cow’s milk fermented with Lactobacillus paracasei CBA L74 on common infectious diseases in children: a multicenter randomized controlled trial. Nutrients 9, 669 (2017). DOI: 10.3390/nu9070669
169. Kirjavainen, P. V., Salminen, S. J. & Isolauri, E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 36, 223–227 (2003). DOI: 10.1097/00005176-200302000-00012
170. Bodemer, C. et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: a randomized study. PLoS ONE 12, e0161555 (2017). DOI: 10.1371/journal.pone.0161555
171. Lau, S. et al. Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 129, 1040–1047 (2012). DOI: 10.1016/j.jaci.2012.02.005
172. Indrio, F., Ladisa, G., Mautone, A. & Montagna, O. Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatr. Res. 62, 98–100 (2007). DOI: 10.1203/pdr.0b013e31806772d3
173. Mullie, C. et al. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr. Res. 56, 791–795 (2004). DOI: 10.1203/01.PDR.0000141955.47550.A0
174. Berni Canani, R. et al. Specific signatures of the gut microbiota and increased levels of butyrate in children treated with fermented cow’s milk containing heat-killed Lactobacillus paracasei CBA L74. Appl. Environ. Microbiol. 83, e01206-17 (2017). DOI: 10.1128/AEM.01206-17
175. Campeotto, F. et al. High faecal calprotectin concentrations in newborn infants. Arch. Dis. Child. Fetal Neonatal Ed. 89, F353–355 (2004). DOI: 10.1136/adc.2002.022368
176. Tsilingiri, K. & Rescigno, M. Postbiotics: what else? Benef. Microbes 4, 101–107 (2013). DOI: 10.3920/BM2012.0046
177. Aguilar-Toalá, J. E. et al. Postbiotics: an evolving term within the functional foods field. Trends Food Sci. Technol. 75, 105–114 (2018). DOI: 10.1016/j.tifs.2018.03.009
178. Collado, M. C., Vinderola, G. & Salminen, S. Postbiotics: facts and open questions. A position paper on the need for a consensus definition. Benef. Microbes 10, 711–719 (2019). DOI: 10.3920/BM2019.0015
179. Foo, H. L., Loh, T. C., Mutalib, N. E. A. & Rahim, R. A. in Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications Ch. 21 (eds Faintuch, J. & Faintuch, S.) 201–211 (Academic, 2019).
180. Johnson, C. N. et al. Administration of a postbiotic causes immunomodulatory responses in broiler gut and reduces disease pathogenesis following challenge. Microorganisms 7, 268 (2019). DOI: 10.3390/microorganisms7080268
181. Wegh, C. A. M., Geerlings, S. Y., Knol, J., Roeselers, G. & Belzer, C. Postbiotics and their potential applications in early life nutrition and beyond. Int. J. Mol. Sci. 20, 4673 (2019). DOI: 10.3390/ijms20194673
182. Zagolski, O., Strek, P., Kasprowicz, A. & Bialecka, A. Effectiveness of polyvalent bacterial lysate and autovaccines against upper respiratory tract bacterial colonization by potential pathogens: a randomized study. Med. Sci. Monit. 21, 2997–3002 (2015). DOI: 10.12659/MSM.893779
183. Krusteva, E. et al. Clinical study of the effect of the preparation DEODAN on leukopenia, induced by cytostatics. Int. J. Immunopharmacol. 19, 487–492 (1997). DOI: 10.1016/S0192-0561(97)00080-5
184. Morisset, M., Aubert-Jacquin, C., Soulaines, P., Moneret-Vautrin, D. A. & Dupont, C. A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. Eur. J. Clin. Nutr. 65, 175–183 (2011). DOI: 10.1038/ejcn.2010.250
185. Roy, P., Aubert-Jacquin, C., Avart, C. & Gontier, C. Benefits of a thickened infant formula with lactase activity in the management of benign digestive disorders in newborns. Arch. Pediatr. 11, 1546–1554 (2004). DOI: 10.1016/j.arcped.2004.10.001
186. Boulloche, J., Mouterde, O. & Mallet, E. Management of acute diarrhea in infants and toddlers – controlled study of the antidiarrheal efficacy of killed Lactobacillus acidophilus (LB strain) versus a placebo and a reference agent (loperamide). Ann. Pediatr. 41, 457–463 (1994).
187. Lievin-Le Moal, V., Sarrazin-Davila, L. E. & Servin, A. L. An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea. Pediatrics 120, e795–803 (2007). DOI: 10.1542/peds.2006-2930
188. Salazar-Lindo, E. et al. Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 44, 571–576 (2007). DOI: 10.1097/MPG.0b013e3180375594
189. Simakachorn, N. et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 30, 68–72 (2000). DOI: 10.1097/00005176-200001000-00020
190. Peng, G. C. & Hsu, C. H. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr. Allergy Immunol. 16, 433–438 (2005). DOI: 10.1111/j.1399-3038.2005.00284.x
191. Rampengan, N. H., Manoppo, J. & Warouw, S. M. Comparison of efficacies between live and killed probiotics in children with lactose malabsorption. Southeast. Asian J. Trop. Med. Public. Health 41, 474–481 (2010).